Patients with Alzheimer's disease (AD) exhibit non-rapid eye movement (NREM) sleep disturbances in addition to memory deficits. Disruption of NREM slow waves occurs early in the disease progression and is recapitulated in transgenic mouse models of beta-amyloidosis. However, the mechanisms underlying slow-wave disruptions remain unknown. Because astrocytes contribute to slow-wave activity, we used multiphoton microscopy and optogenetics to investigate whether they contribute to slow-wave disruptions in APP/PS1 mice. The power but not the frequency of astrocytic calcium transients was reduced in APP/PS1 mice compared to nontransgenic controls. Optogenetic activation of astrocytes at the endogenous frequency of slow waves restored slow-wave power, reduced amyloid deposition, prevented neuronal calcium elevations, and improved memory performance. Our findings revealed malfunction of the astrocytic network driving slow-wave disruptions. Thus, targeting astrocytes to restore circuit activity underlying sleep and memory disruptions in AD could ameliorate disease progression.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421876 | PMC |
| http://dx.doi.org/10.1038/s41598-023-40402-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Single Night in Hypoxia Either with or without Ketone Ester Ingestion Reduces Sleep Quality Without Impacting Next Day Exercise Performance.
Med Sci Sports Exerc
November 2024
Exercise Physiology Research Group, Department of Movement Sciences, KU Leuven, Leuven, BELGIUM.
Background: Sleeping at altitude is highly common in athletes as an integral part of altitude training camps or sport competitions. However, concerns have been raised due to expected negative effects on sleep quality, thereby potentially hampering exercise recovery and next-day exercise performance. We recently showed that ketone ester (KE) ingestion beneficially impacted sleep following strenuous, late evening exercise in normoxia, and alleviated hypoxemia.
View Article and Find Full Text PDFRole of sleep and neurochemical biomarkers in synaptic plasticity related to neurological and psychiatric disorders: A scoping review.
J Neurochem
January 2025
Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.
Sleep is vital for maintaining physical and mental well-being, impacting cognitive functions like memory and learning through neuroplasticity. Sleep disturbances prevalent in neurological and psychiatric disorders exacerbate cognitive decline, imposing societal burdens. Exploring the relationship between sleep and neuroplasticity elucidates the mechanisms influencing cognition, particularly amidst the prevalent sleep disturbances in these clinical populations.
View Article and Find Full Text PDFMyocardial infarction augments sleep to limit cardiac inflammation and damage.
Nature
November 2024
Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Article Synopsis
- Sleep plays a crucial role in heart health, especially after a heart attack (myocardial infarction), by influencing inflammatory responses and healing processes.
- After a heart attack, certain immune cells (monocytes) are recruited to the brain to promote sleep, which helps reduce harmful stress on the heart and supports recovery.
- Disruption of sleep can worsen heart function and increase the risk of further cardiovascular issues, as poor sleep can reprogram immune cells in a way that enhances inflammation and hinders the healing process.
Pharmacological Management of Sleep-Wake Disturbances in Delirium.
J Clin Pharmacol
October 2024
Psychiatry Service, VA Boston Healthcare System, West Roxbury, MA, USA.
Article Synopsis
- Delirium is a complex syndrome marked by changes in attention and awareness, often accompanied by sleep issues like circadian rhythm inversion and sleep fragmentation.
- There are currently no FDA-approved drugs specifically for delirium or its associated sleep disturbances; management mainly involves treating underlying medical problems and promoting proper sleep patterns through non-drug approaches.
- Some medications like ramelteon, melatonin, dexmedetomidine, and dual orexin receptor antagonists show promise in helping manage these sleep disruptions, particularly in ICU patients, although their evidence of effectiveness varies.
Optogenetic targeting of cortical astrocytes selectively improves NREM sleep in an Alzheimer's disease mouse model.
Sci Rep
October 2024
Department of Neurology, MassGeneral Institute of Neurodegenerative Diseases, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Alzheimer's disease (AD) is a progressive neurodegenerative condition marked by memory impairments and distinct histopathological features such as amyloid-beta (Aβ) accumulations. Alzheimer's patients experience sleep disturbances at early stages of the disease. APPswe/PS1dE9 (APP) mice exhibit sleep disruptions, including reductions in non-rapid eye movement (NREM) sleep, that contribute to their disease progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!